Bausch + Lomb Q2 revenue $1.394B (+9% YoY); raises FY2026 guidance

Bausch & Lomb Corp

Revenue $1.394B, up 9% reported and 8% constant currency YoY; GAAP net loss $14M vs $62M loss.
Adjusted EBITDA $241M (+$50M YoY); Adjusted EBITDA ex-IPR&D $246M.
Surgical revenue +19% (premium IOLs up 175%); Pharmaceuticals +15% (MIEBO/XIIDRA +27% H1).
FY2026 revenue guidance raised to $5.44B-$5.54B; Adj. EBITDA ex-IPR&D raised to $1.025B-$1.075B.
Cash flow from operations $153M, up from $35M; GAAP EPS ($0.04), adjusted EPS $0.15.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.